Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France - Cross-sectional Study
Phase of Trial: Phase IV
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Apixaban (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.
- 27 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.